Paul Mampilly Went to Fordham University, where he received his Master in Business Administration. Back in the year 1991, he worked for Bankers Trust as an assistant portfolio manager. As he continued with his career amassing a wealth of experience as well as knowledge in the investment industry, he managed to secure a crucial position at legal firms such as Deutsche Bank.
Currently, Paul Mampilly is still involved in the world of finance where he works as an analyst. His work focuses on assisting ordinary people to grow their wealth. He spends more time teaching them how they can make money on their own so that they can live better lives. Most of his newsletters offer essential advice as well as investment guidelines that help people who are in the investment industry make sound decisions on investments.
Since the year 2016, when Paul Mampilly started working with Banyan Hill Publishing, more than 90,000 people subscribed for Mampilly’s newsletter Profits Unlimited. In his newsletter he discusses in detail current investment opportunities, he even suggests to his readers, lists of stocks that they can buy.
Paul Mampilly recommends to the new investors to pay more attention to technology as well as innovative trends. He gave an excellent example of cell phone companies. Those investors who bought shares from cell phone manufacturing corporations in the past few years are now earning unimaginable profits.
Paul gave precision medicine as one of the technology trends in the world today. Precision medicine includes genetic testing as one way of diagnosing diseases such as different forms of cancer. Patient’s genetic profile helps the medical professionals in understanding the personal DNA code of a patient. Doctors use this piece of information in comparing the DNA of a patient to genetic information that is in their database.
With this process, a specialist will be able to find the right treatment for each patient. Instead of a doctor guessing the right medicine that can cure the patient’s illness, it is now possible to target the proper cure and match it perfectly. In connection with this information, Paul Mampilly recommends that people should spend more money to buy stocks from companies representing genetic testing firms.